Connect with us

Hi, what are you looking for?

Wednesday, Feb 8, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


PharmAla Biotech gets Health Canada approval to export large MDMA shipment to the U.K.

The company believes this to be the largest shipment of MDMA the government department has ever approved

PharmAla Biotech gets Health Canada approval to export large MDMA shipment to the U.K.
MDMA crystal, tested in Holland. Photo by HarrieW via Wikimedia Commons

PharmAla Biotech Holdings Inc. (CSE: MDMA) has received approval from Canadian government authorities to ship 300 grams of its LaNeo MDMA drug to an unnamed client in the United Kingdom for research purposes.

On Tuesday, the Vancouver company announced receiving Health Canada approval for what it believes to be the heaviest shipment of MDMA the government department has ever permitted.

“We’re incredibly proud of this milestone. It is additional proof that the clinical development of MDMA is moving forward. PharmAla exists to assist our client researchers around the world by not only saying we’ll provide them with research materials, but actually delivering.” said Nick Kadysh, CEO of PharmAla Biotech.

“The global psychedelics industry is still in its infancy, but strong demand for these molecules helps ensure a foundational role for manufacturers like PharmAla.”

Read more: PharmAla and Mindset enter psilocybin distribution agreement

Read more: PsyCan aims to be ‘go-to’ psychedelics industry organization, receives support from lawmakers

This morning, PharmAla’s CEO and director of sales hosted a webinar on planning clinical trials involving psychedelics with the CEO of Mindset Pharma (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF), James Lanthier.

Mindset and PharmAla entered a psilocybin distribution agreement last November.

PharmAla is the first publicly traded company to manufacture GMP-certified MDMA. The company’s CEO Nick Kadysh is the board chair of Psychedelics Canada, the only national-level trade association for legal psychedelics internationally.

PharmAla’s stock dropped by 20 per cent today to $0.04 while Mindset’s stock stayed flat at $0.30 on the Canadian Securities Exchange.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter





Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The drug will be used to help establish a safe supply for patients in Canada and Australia


Psychiatrists can now prescribe MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression


The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression


The program's creation was inspired by new regulations for psychedelic-assisted therapy in Alberta